Hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. OCTOBER., 2000, Pages

  Tang, Z Y ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Hepatectomy; Hepatocellular carcinoma; Metastasis; Multimodality treatment; Recurrence; Screening; Second look resection

Indexed keywords

AFLATOXIN; ALPHA FETOPROTEIN; ALPHA2B INTERFERON; DOXORUBICIN; PACLITAXEL; TAMOXIFEN; THYMOSIN ALPHA1;

ALGA; CANCER MORTALITY; CANCER RECURRENCE; CANCER SCREENING; CHINA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; ECHOGRAPHY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS G VIRUS; HIGH RISK POPULATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SECOND LOOK SURGERY; WATER CONTAMINATION;

EID: 0033679575     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02257.x     Document Type: Conference Paper

References (101)

1. Mortality of primary liver cancer in China from 1990 through 1992
2. Cancer incidence trend in Shanghai 1972-94
3. Cancer statistics, 1998
4. Transactivation of transforming growth factor alpha gene by hepatitis B virus preS1
5. Chronic infection with hepatitis G virus in relation to hepatocellular carcinoma among non-Asians in Los Angeles County California
6. High prevalence of transfusion-transmitted virus among patients with non-B, non-C hepatocellular carcinoma
7. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans
8. Chronic liver diseases for the risk of hepatocellular carcinoma: A case-control study in Japan. Etiologic association of alcohol consumption, cigarette smoking and the development of chronic liver diseases
9. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case-control study in Italy
10. Diabetes mellitus and the risk of primary liver cancer
11. Association between high serum alanine aminotransferase levels and more rapid development and high rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis
12. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: A multivariate analysis in 343 patients
13. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus
14. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by Oltipraz in residents of Qidong, P
15. Numerical aberrations of chromosomes 16, 17, and 18 in hepatocellular carcinoma: A FISH and FCM analysis of 20 cases
16. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells
17. Neoangiogenesis and sinusoidal capillarization in dysplastic nodules of the liver
18. Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry
19. Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: Matched case-control study, pathological analysis, and pathogenetic hypothesis
20. The usefulness of determinating des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma
21. Measurement of serum levels of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity
22. Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma
23. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients
24. Imaging of hepatocellular carcinoma
25. Diagnostic value and tolerance of lipiodol-computed tomography for the detection of small hepatocellular carcinoma: Correlation with pathologic examination of explanted livers
26. Circulating vascular endothelial growth factor is a possible tumor marker for metastasis in human hepatocellular carcinoma
27. Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients
28. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration
29. Natural killer cell activity in patients with hepatocellular carcinoma. A new prognostic indicator after hepatectomy
30. Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: Correlation with angiostatin generation and its clinical significance
31. Expression of urokinase-type plasminogen activator (uPA), uPA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma
32. Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma
33. KAI1, a new metastasis suppressor gene, is related in metastatic hepatocellular carcinoma
34. Quantitation of telomerase activity in hepatocellular carcinoma: A possible aid for a prediction of recurrent diseases in the remnant liver
35. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma
36. Microvessel density of hepatocellular carcinoma: Its relationship with prognosis
37. Kai-1 gene expression in hepatocellular carcinoma and its relationship with intrahepatic metastases
38. Urokinase-type plasminogen activator, its receptor and inhibitor expression in hepatocellular carcinoma relation to cancer invasiveness and prognosis
39. Invasion and metastasis of liver cancer: Expression of intercellular adhesion molecule 1
40. Efficacy of a surveillance program for early detection of hepatocellular carcinoma
41. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis
42. Outcome of 67 patients with hepatocellular carcinoma detected during screening of 1125 patients with chronic hepatitis
43. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis - An evaluation
44. Prospective study of early detection for primary liver cancer
45. Screening and early diagnosis of primary liver cancer
46. Analysis of factors affecting outcome after hepatectomy of patients with liver cirrhosis and small hepatocellular carcinoma
47. Early hepatocellular carcinoma as an entity with a high rate of surgical cure
48. Indications for hepatectomy for hepatocellular carcinoma - What stage of the disease is the best indication for surgery?
49. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma
50. Hepatic resection for hepatocellular carcinoma - Japanese experience
51. Segmental liver resections, present and future: Caudate lobe resection for liver tumors
52. Major liver resections without vascular clamping: Retrospective study of 84 cases
53. Preoperative portal vein embolization: An audit of 84 patients
54. Improved survival with resection after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
55. Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis
56. Hepatocellular carcinoma: Comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization
57. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: A retrospective analysis
58. Should hepatomas be treated with hepatic resection or transplantation
59. Cyclosporine induces cancer progression by a cell-autonomous mechanism
60. The value of postoperative regional chemotherapy in prevention of recurrence after radical resection for primary liver cancer
61. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues
62. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expression of the factors associated with metastasis
63. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: With relation to tumor size and invasiveness
64. Study of angiogenesis induced by metastatic and nonmetastatic liver cancer by corneal micropocket model in nude mice
65. Surgical treatment of hepatocellular carcinoma and related basic research with special reference to recurrence and metastasis
66. Apoptosis of human BEL-7402 hepatocellular carcinoma cells released by antisense H-ras DNA - In vitro and in vivo studies
67. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20
68. Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma
69. Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma
70. Treatment of hepatocellular carcinoma: A single-center experience
71. The role of hepatic arterial embolization in the treatment of spontaneous rupture of hepatocellular carcinoma
72. Hepatocellular carcinoma with portal vein tumor thrombus: Embolization of arterioportal shunts
73. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: A prospective controlled study
74. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, control trial in a single institution
75. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial
76. Acute hepatic failure following transcatheter arterial embolization for the treatment of hepatocellular carcinoma
77. Ruptured hepatocellular carcinoma as a complication of transarterial oily chemoembolization
78. Clinical and microbiological features of liver abscess after transarterial chemoembolization for hepatocellular carcinoma
79. Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma
80. Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection
81. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma
82. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: Comparison with percutaneous ethanol injection therapy
83. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode
84. Cryotherapy for primary liver cancer
85. The usefulness of radiation therapy for hepatocellular carcinoma
86. Radiotherapy for osseous metastases from hepatocellular carcinoma: A retrospective study of 57 patients
87. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma
88. Radiation tolerance of cirrhotic livers in relation to the preserved functional capacity: Analysis of patients with hepatocellular carcinoma treated by focused proton beam radiotherapy
89. Hepatic radioembolization with Yttrium-90 glass microsphere for treatment of primary liver cancer
90. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma
91. Phase II and pharmacokinetic study of Paclitaxel therapy for unresectable hepatocellular carcinoma patients
92. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma
93. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: A preliminary experience
94. Clinical evaluation of CTL therapy for patients with liver cancer
95. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma
96. Tamoxifen in treatment of hepatocellular carcinoma: A randomized controlled trial (CLIP Group)
97. Treatment of hepatocellular carcinoma with octreotide: A randomized controlled study
98. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - A single center analysis including 132 patients
99. Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: Local therapeutic effect and long-term survival rate
100. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma